DGIdb - ALEFACEPT Drug Record

ALEFACEPT chembl:CHEMBL1201571 ApprovedImmunotherapy

Alternate Names:

LFA3TIP
BG-9273
LFA-3TIP
AMEVIVE
BG-9712
ALEFACEPT
LFA-3CD2
ASP0485
chembl:CHEMBL1201571
rxcui:299635
chemidplus:222535-22-0
drugbank:00092

Drug Info:

Drug Class	immunosuppressive agents
Year of Approval	2003
Drug Categories	psoriasis
FDA Approval	2003
Drug Class	fusion protein
Drug Indications	Immunosuppressive Agents
Drug Categories	carbohydrates
Drug Groups	investigational
Drug Categories	antibodies
Drug Categories	blood proteins
Drug Categories	cd2-directed antibody interactions
Drug Categories	cd2-directed lfa-3/fc fusion protein
Drug Categories	cd58 antigens
Drug Categories	dermatologicals
Drug Categories	globulins
Drug Categories	glycoconjugates
Drug Categories	glycoproteins
Drug Categories	immunoglobulin isotypes
Drug Categories	immunologic factors
Drug Categories	immunoproteins
Drug Categories	membrane glycoproteins
Drug Categories	membrane proteins
Drug Categories	recombinant fusion proteins
Drug Categories	serum globulins

(3 More Sources)

Publications:

Goedkoop et al., 2004, Alefacept therapy reduces the effector T-cell population in lesional psoriatic epidermis., Arch. Dermatol. Res.
Ortonne, 2003, Clinical response to alefacept: results of a phase 3 study of intramuscular administration of alefacept in patients with chronic plaque psoriasis., J Eur Acad Dermatol Venereol
Chamian et al., 2007, Alefacept (anti-CD2) causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis., J Transl Med
da Silva et al., 2002, Alefacept, an immunomodulatory recombinant LFA-3/IgG1 fusion protein, induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2(+) cells., J. Immunol.
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Larsen et al., 2007, Changes in circulating lymphocyte subpopulations following administration of the leucocyte function-associated antigen-3 (LFA-3)/IgG1 fusion protein alefacept., Clin. Exp. Immunol.
Vaishnaw et al., 2002, Pharmacokinetics, biologic activity, and tolerability of alefacept by intravenous and intramuscular administration., J Pharmacokinet Pharmacodyn
Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov

ALEFACEPT CD2

Interaction Score: 52.07

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction T-cell surface antigen CD2 inhibitor

Specific Action of the Ligand Inhibition

PMIDs:
14968366 12795770 17555598 11970990 11752352 17403057

Sources:
TEND TdgClinicalTrial DrugBank GuideToPharmacology ChemblInteractions
ALEFACEPT CD58

Interaction Score: 7.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
ALEFACEPT FCGR3A

Interaction Score: 2.22

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12795239 11970990 17139284 17016423

Sources:
DrugBank
ALEFACEPT FCGR3B

Interaction Score: 0.98

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11970990

Sources:
DrugBank

DrugBank: DB00092

Version: 5.1.7

Alternate Names:

ALEFACEPT DrugBank Drug Name

222535-22-0 CAS Number

Amevive Drug Brand

Drug Info:

Drug Type biotech

Drug Groups approved

Drug Groups investigational

Publications:

Vaishnaw et al., 2002, Pharmacokinetics, biologic activity, and tolerability of alefacept by intravenous and intramuscular administration., J Pharmacokinet Pharmacodyn

da Silva et al., 2002, Alefacept, an immunomodulatory recombinant LFA-3/IgG1 fusion protein, induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2(+) cells., J. Immunol.

Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov

TEND: ALEFACEPT
- Version: 01-August-2011
Alternate Names:

ALEFACEPT Primary Drug Name

Drug Info:

Year of Approval 2003

Drug Class immunosuppressive agents

Publications:
TdgClinicalTrial: ALEFACEPT
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications Immunosuppressive Agents

Drug Class fusion protein

FDA Approval 2003

Publications:
TTD: Alefacept
- Version: 2020.06.01
Alternate Names:

D09ZSO TTD Drug ID

Drug Info:

Publications:
GuideToPharmacology: 178103393
- Version: 29-September-2020
Alternate Names:

ALEFACEPT GuideToPharmacology Ligand Name

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL1201571
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL1201571
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:

Direct Interaction	yes
Mechanism of Interaction	T-cell surface antigen CD2 inhibitor
Specific Action of the Ligand	Inhibition

ALEFACEPT	DrugBank Drug Name
222535-22-0	CAS Number
Amevive	Drug Brand

Drug Type	biotech
Drug Groups	approved
Drug Groups	investigational

ALEFACEPT Drug Record

ALEFACEPT chembl:CHEMBL1201571 ApprovedImmunotherapy

Alternate Names:

Drug Info:

Publications:

ALEFACEPT CD2

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction yes Mechanism of Interaction T-cell surface antigen CD2 inhibitor Specific Action of the Ligand Inhibition

PMIDs: 14968366 12795770 17555598 11970990 11752352 17403057

Sources: TEND TdgClinicalTrial DrugBank GuideToPharmacology ChemblInteractions

ALEFACEPT CD58

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: TTD

ALEFACEPT FCGR3A

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 12795239 11970990 17139284 17016423

Sources: DrugBank

ALEFACEPT FCGR3B

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 11970990

Sources: DrugBank

DrugBank: DB00092

Alternate Names: ALEFACEPT DrugBank Drug Name 222535-22-0 CAS Number Amevive Drug Brand

Drug Info: Drug Type biotech Drug Groups approved Drug Groups investigational

TEND: ALEFACEPT

Alternate Names: ALEFACEPT Primary Drug Name

Drug Info: Year of Approval 2003 Drug Class immunosuppressive agents

Publications:

TdgClinicalTrial: ALEFACEPT

Alternate Names:

Drug Info: Drug Indications Immunosuppressive Agents Drug Class fusion protein FDA Approval 2003

Publications:

TTD: Alefacept

Alternate Names: D09ZSO TTD Drug ID

Drug Info:

Publications:

GuideToPharmacology: 178103393

Alternate Names: ALEFACEPT GuideToPharmacology Ligand Name

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL1201571

Alternate Names:

Drug Info:

Publications:

ChemblInteractions: CHEMBL1201571

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction T-cell surface antigen CD2 inhibitor

Specific Action of the Ligand Inhibition

PMIDs:
14968366 12795770 17555598 11970990 11752352 17403057

Sources:
TEND TdgClinicalTrial DrugBank GuideToPharmacology ChemblInteractions

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TTD

Interaction Types & Directionality:

n/a

PMIDs:
12795239 11970990 17139284 17016423

Sources:
DrugBank

Interaction Types & Directionality:

n/a

PMIDs:
11970990

Sources:
DrugBank

Alternate Names:

ALEFACEPT DrugBank Drug Name

222535-22-0 CAS Number

Amevive Drug Brand

Drug Info:

Drug Type biotech

Drug Groups approved

Drug Groups investigational

Alternate Names:

ALEFACEPT Primary Drug Name

Drug Info:

Year of Approval 2003

Drug Class immunosuppressive agents

Drug Info:

Drug Indications Immunosuppressive Agents

Drug Class fusion protein

FDA Approval 2003

Alternate Names:

D09ZSO TTD Drug ID

Alternate Names:

ALEFACEPT GuideToPharmacology Ligand Name